Stay updated with breaking news from Cognitive Function Score. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
No severe adverse events reported to date Topline data expected as early as Q1 2024 OCALA, Fla., Nov. 21, 2023 -- AIM ImmunoTech Inc. today announced the last subject has completed treatment...
Topline data expected as early as Q1 2024OCALA, Fla., Aug. 08, 2023 -- AIM ImmunoTech Inc. today announced the completion of enrollment in the company’s Phase 2 study evaluating Ampligen® as a...
Topline data expected as early as Q1 2024...
Preliminary Ampligen data demonstrates potential to be an effective treatment option for post-COVID conditions Enrollment expected to be completed in Q4 2023 OCALA, Fla., July 10, 2023 ...
Company expects to commence patient enrollment and dosing in Q1 2023...